YL 205
Alternative Names: YL-205Latest Information Update: 31 Jul 2026
At a glance
- Originator MediLink Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 02 Jun 2026 Adverse events and efficacy data from a phase I/II trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 18 Jun 2024 MediLink Therapeutics plans a phase I/II trial for solid tumours (Late-stage disease, Metastatic disease) in China in July 2024 (IV, Infusion) (NCT06459973)
- 04 Jun 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (IV)(NCT06459973)